Thrombosis News and Research

Latest Thrombosis News and Research

New research seeks customised treatment of cardiovascular diseases

The Centre for Cooperative Research in Biomaterials, CIC biomaGUNE, is involved in the research consortium of cvREMOD, which aims to move forward in the attainment of new diagnosis techniques for prevention and customised treatment of cardiovascular diseases in the upcoming four years.

21 May 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Elevated levels of Lp-PLA2 associated with increased risk of coronary heart disease

A meta-analysis of approximately 80,000 individuals from 32 prospective studies was published in The Lancet on May 1, 2010. The data shows that elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated with an increased risk of coronary heart disease similar in magnitude to that with non-HDL cholesterol or systolic blood pressure.

20 May 2010

AngioDynamics launches Morpheus Smart PICC Triple Lumen CT PICC

AngioDynamics announced today the launch of the first member of its new generation of peripherally inserted central catheters (PICCs) for procedures involving the use of contrast media in computed tomography (CT) - the Morpheus Smart PICC Triple Lumen CT PICC.

17 May 2010

Roche to commence clinical study of TB-403 in patients with colorectal and ovarian cancer

BioInvent International AB and ThromboGenics NV announce today that their partner Roche will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancer.

17 May 2010

Statins may play role in lowering risk of clot-related diseases: Study

Individuals at risk for clot-related diseases may benefit from taking common cholesterol-lowering drugs known as statins, according to a study conducted by researchers at the University of Connecticut.

17 May 2010

Risk of venous thromboembolism is low after hepatic resection in cirrhotic patients: Researchers

Hepatocellular carcinoma is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulative function. Surgical resection is the best option to cure HCC, however, surgery on cirrhotic liver may increase the risk of bleeding.

12 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

6 May 2010

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

Findings from Abbott's SPIRIT IV trial, one of the largest randomized clinical trials comparing two drug eluting stents, with 3,690 U.S.-based patients, were published today in The New England Journal of Medicine.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Non-compliance, NSAIDs use inhibit clinical benefit of aspirin

Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science at Florida Atlantic University, was the first to demonstrate that aspirin prevents a first heart attack based on his landmark Physicians Health Study (PHS).

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Celera reports net loss of $12.5M for first-quarter 2010

Celera Corporation today reported net revenues of $31.4 million for the first quarter of 2010 that ended March 27, 2010, compared to $45.7 million in the prior year quarter. For the first quarter of 2010, Celera reported a net loss $12.5 million, or $0.15 per share, compared to a net loss of $1.4 million, or $0.02 per share, for the prior year quarter.

28 Apr 2010

FDA clears Osmetech's eSensor Thrombophilia Risk Test

Osmetech, plc today announced that the US Food and Drug Administration (FDA) has cleared the eSensor® Thrombophilia Risk Test (TRT), a multiplexed molecular diagnostic test for four genetic markers associated with thrombosis. The panel includes Factor V Leiden, Factor II Prothrombin, MTHFR 677 and MTHFR 1298 in a single test panel.

26 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Thrombosis News and Research

Latest Thrombosis News and Research

New research seeks customised treatment of cardiovascular diseases

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Elevated levels of Lp-PLA2 associated with increased risk of coronary heart disease

AngioDynamics launches Morpheus Smart PICC Triple Lumen CT PICC

Roche to commence clinical study of TB-403 in patients with colorectal and ovarian cancer

Statins may play role in lowering risk of clot-related diseases: Study

Risk of venous thromboembolism is low after hepatic resection in cirrhotic patients: Researchers

Merck hosts R&D and Business Briefing

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Non-compliance, NSAIDs use inhibit clinical benefit of aspirin

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Celera reports net loss of $12.5M for first-quarter 2010

FDA clears Osmetech's eSensor Thrombophilia Risk Test

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Thrombosis News and Research

Latest Thrombosis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in